Prevalence of detectable c-peptide according to age at diagnosis and duration of type 1 diabetes

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 476-481

  Davis, Asa K ^a   DuBose, Stephanie N ^b   Haller, Michael J ^c   Miller, Kellee M ^b   DiMeglio, Linda A ^d   Bethin, Kathleen E ^e   Goland, Robin S ^f   Greenberg, Ellen M ^f   Liljenquist, David R ^g   Ahmann, Andrew J ^h   Marcovina, Santica M ⁱ   Peters, Anne L ^j   Beck, Roy W ^b   Greenbaum, Carla J ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f Department of Medicine   (United States)

^g Rocky Mt Diabet Osteoporosis Ctr   (United States)

^h Harold Schnitzer Diabetes Health Center   (United States)

ⁱ Northwest Lipid Metabolism and Diabetes Research Laboratories   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; INSULIN;

ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GROUPS BY AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PROTEIN BLOOD LEVEL; PROVOCATION TEST; VERY ELDERLY; ADOLESCENT; BLOOD; DIABETES MELLITUS, TYPE 1; MIDDLE AGED; PANCREAS ISLET BETA CELL; PRESCHOOL CHILD; SECRETION (PROCESS); YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 84930760699     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1952     Document Type: Article

References (19)

1. Palmer JP. C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 2009; 25:325-328.
2. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013;30:803-817.
3. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of betacell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971.
4. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: Report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264.
5. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836.
6. Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63:739-748.
7. Vantyghem M-C, Raverdy V, Balavoine A-S, et al. Continuous glucose monitoring after islettransplantation in type 1 diabetes: An excellent graft function (b-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (b-score greater than 3). J Clin Endocrinol Metab 2012;97:E2078-E2083.
8. Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066-2073.
9. Ludvigsson J, Carlsson A, Deli A, et al. Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents. Diabetes Res Clin Pract 2013;100:203-209.
10. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic b-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853.
11. McGee P, Steffes M, NowickiM, et al.; DCCT/EDIC Research Group. Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: A pilot study. Diabet Med 2014;31:1264-1268.
12. Greenbaum CJ, Anderson AM, Dolan LM, et al.; SEARCH Study Group. Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009;32: 1839-1844.
13. Dabelea D, Mayer-Davis EJ, Andrews JS, et al. Clinical evolution of beta cell function in youth with diabetes: The SEARCH for Diabetes in Youth study. Diabetologia 2012;55:3359-3368.
14. Oram RA, Jones AG, Besser REJ, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014;57: 187-191.
15. Barker A, Lauria A, Schloot N, et al. Agedependent decline of b-cell function in type 1 diabetes after diagnosis: A multi-centre longitudinal study. Diabetes Obes Metab 2014;16: 262-267.
16. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012;97:4383- 4389.
17. American Diabetes Association. Standards of medical care in diabetesd2014. Diabetes Care 2014;37(Suppl.1):S14-S80.
18. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012;35: 465-470.
19. Decision Memo for Insulin Pump: C-Peptide Levels as a Criterion for Use (CAG-00092R) [Internet], 2004. Washington, DC, Centers for Medicare and Medicaid Services. Available from http://www.cms.gov/medicare-coveragedatabase/details/nca-decision-memo.aspx?NCAId=109&IsPopup=y&NCDId=223&NcaName=Insulin+Pump∗3a$+C-Peptide+Levels+as+a+Criterion+for+Use&ncdver=2&bc=AAAAAAAACAAAAA%3D%3D&. Accessed 3 April 2014.